Table 4.
Liposomal formulations used for the treatment of diabetic wounds in animal models
| Composition | Biomolecule | Animal Model | Area (cm2) | Time*(Days) | References |
|---|---|---|---|---|---|
| DOTAP+sodium cholate | Keap1 siRNA | Mice+stent+diabetes 2 (db/db) | 0.8 | 24 | 132 |
| Unknown | microRNA miR-132 | Mice+diabetes 2 (db/db) | 0.13 | 6 | 23 |
| RGDK-lipopeptide+cholesterol | PDGF-B gen | Rat+diabetes 1 (STZ) | 13.9 | 10 | 133 |
| Phosphatidylcholine+cholesterol+tween80+stearylamine | Bacteriophages | Mice+infected+diabetes 1 | 0.2 | 7 | 134 |
| Phosphatidylcholine+DOTAP | ATP | Rabbit+ischemic+diabetes 1 | 0.3 | 15 | 136 |
| Hyaluronic acid+cholesterol+DOTAP+hydrogenated phosphatidylcholine | EGF, IGF-1 PDGF-A | Mice+diabetes 1 | 0.5 | 11 | 138 |
| Phosphatidylcholine+cholesterol+phosphatidate+phosphoethanolamine-n-(lissamine rhodamine b sulfonyl) | SDF-1 | Mice+diabetes 2 | 1 | 21 | 139 |
| Phosphocholine+phosphoethanolamine+cholesterol+sphingomyelin | Syndecan-4 PDGF-BB | Mice+stent+diabetes 2 (ob/ob) | 0.2 | 14 | 140 |
Diabetes type 1 was inducted with aloxan (rabbits) or streptozocin (mice and rats) (*times for complete wound closure or more than 90% of full thickness wounds).
ATP, adenosine triphosphate; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; IGF-1, insulin-like growth factor-1; RGDK, Arg-Gly-Asp-Lys.